CLINICAL TRIALS
Could cancer finally have a targeted cure? Groundbreaking study reveals potential pathway to stop tumor growth without harming healthy cells
A breakthrough in cancer research offers new hope. Scientists have created compounds that halt tumor growth while protecting healthy cells. This experimental therapy is now entering human trials. If successful, it could treat many cancers. The approach targets the RAS gene, crucial in about one in five cancers. This innovation promises a new era in cancer treatment.
India develops first indigenously discovered antibiotic "Nafithromycin" effective against resistant respiratory infections
India has proudly introduced Nafithromycin, its first homegrown antibiotic, tackling stubborn respiratory infections with groundbreaking efficacy. Coupled with a significant leap in gene therapy for Haemophilia, these innovations underscore India's commitment to self-sufficiency in the pharmaceutical arena. The country is now embracing a model that fosters collaboration with the private sector, setting the stage for international acclaim in biomedical research.
Tiny fruit, healthier bread, and a daily drink: Study reveals 3 surprising natural remedies to beat constipation
A new guideline from the British Dietetic Association identifies three simple remedies for constipation: kiwi, rye bread, and mineral-rich water. Published in the Journal of Human Nutrition and Dietetics, the findings challenge the long-held “more fiber” advice by showing these specific foods work better than generic diets. With evidence from 75 trials, the recommendations offer an easy, natural way to support digestion, providing practical relief for millions worldwide.
Prerna launches CANTEL™: A MicroRNA-based blood test for breast cancer screening
PrecisionRNA Biotech from Hyderabad has launched Cantel, a new microRNA blood test for breast cancer screening. This test offers a simple and accurate alternative to traditional methods. It aims to improve early detection rates in India. Cantel is designed for women aged 30 and above. The company is seeking investors for nationwide expansion.
Praxis Precision Medicines stock jumps over 235% today- Here’s why investors are paying attention
PRAX stock: Praxis Precision Medicines stock saw a massive surge of over 235 percent. This happened after positive results from a Phase 3 clinical trial for ulixacaltamide, a drug for essential tremor. The company plans to submit a New Drug Application to the FDA by early 2026. Analysts have given the stock a strong buy rating.
CDSCO seeks views on level playing field for new drugs
In a significant shift for the pharmaceutical market, India's drug regulator is crafting new legislation regarding drug approvals. Under this proposal, the first entity to introduce a novel drug will be mandated to perform clinical trials, while subsequent entrants will be allowed to forego these tests.
AI lab Lila Sciences tops $1.3 billion valuation with new Nvidia backing
The latest funding brings Lila's total Series A to $350 million and overall capital raised to $550 million, reflecting strong investor appetite for AI-driven scientific discovery.
Deadly fatty liver could be reversed with this surprising two-drug heart combo, as per doctors
Doctors have found hope for fatty liver disease using two common heart drugs. The new study from the University of Barcelona shows this combo might help reduce liver fat and improve liver health. More tests on humans are needed, but experts say it could be a big step in treating fatty liver safely.
Nagaland University-led study finds tea blossoms rich in health-boosting compounds
A new study reveals tea blossoms hold significant health potential. These flowers, usually discarded, are packed with beneficial compounds. Researchers believe they can be used for natural health supplements and drinks. This discovery could reduce agricultural waste and boost rural economies. India is poised to become a leader in these new plant-based products.
Novo Nordisk to acquire Akero Therapeutics for $4.7 billion — Akero stock jumps 20%, Novo Nordisk stock falls, here’s all about the deal
Akero Therapeutics stock surged nearly 20% today. Novo Nordisk announced it will acquire Akero for $4.7 billion in cash. The deal values Akero shares at $54 each, plus up to $6 more if FDA approves Akero’s lead drug, Efruxifermin, for metabolic disease treatment. This acquisition strengthens Novo Nordisk’s position in metabolic and liver diseases. The buyout is expected to close by early 2026, pending approvals. Novo Nordisk anticipates higher R&D costs in 2026 but no impact on 2025 profits.
China surgeons perform first Pig-to-Human Liver Transplant. Ray of hope for cancer patients?
American surgeons have in recent years transplanted hearts and kidneys from genetically modified pigs into a small number of living patients, they have shied away from liver xenotransplantation, which poses particularly complex challenges.
Ahmedabad civic body receives complaints about 'lapses' by labs in clinical trials on humans
Ahmedabad Municipal Corporation has alerted the Gujarat FDCA regarding complaints of clinical trial lapses. Allegations include inadequate care for participants during and after trials, and unauthorized videography of subjects. The corporation has forwarded these details for further investigation and action.
Forget long workouts: Study says 5-minute ‘exercise snacks’ can boost heart and muscle health more effectively
A new study published in BMJ Sports Medicine suggests that short, deliberate bursts of activity — dubbed “exercise snacks” — can significantly enhance fitness, especially for inactive adults. These quick routines, lasting under five minutes, such as stair climbing or brisk walking, were shown to boost heart and muscle health, improve endurance, and encourage consistency, offering an easier, time-efficient alternative to traditional long workouts.
Scientists reverse Alzheimer’s in mice — breakthrough sparks hope for humans
A new treatment shows promise in reversing Alzheimer's disease. Scientists used nanoparticles to help the brain clear toxic buildup. This therapy restored the blood-brain barrier's function in mice. Researchers observed significant improvements in brain function and behavior. Human trials could begin in a few years, offering hope for a cure.
Nobel winner Fred Ramsdell unreachable, hiking 'off the grid'
Fred Ramsdell, a Nobel laureate for immune system research, is currently unreachable. He is on an off-the-grid hiking trip and unaware of his 2025 Nobel Prize win. The Nobel committee and his colleagues are trying to contact him. Ramsdell shared the prize with Mary Brunkow and Shimon Sakaguchi for their work on regulatory T-cells.
Huntington's disease cure is possible through new treatment, reveals study. Check symptoms, what causes illness
Huntington's disease findings were announced last month in a news release from uniQure, the company that sponsored the research.
Nobel Prize 2025 in Medicine awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi for discoveries in immune tolerance
The 2025 Nobel Prize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance,” a breakthrough that has transformed understanding of how the body prevents the immune system from attacking its own tissues.
Harvard-trained doctor suggest 10 foods to reduce bloating, improve digestion
Harvard-trained gastroenterologist Dr. Saurabh Sethi recommends 10 foods to help reduce common post-meal bloating and improve digestion. These include enzyme-rich fruits like kiwi and papaya, hydrating cucumber, fiber-packed chia seeds and oats, and soothing ginger and peppermint. These natural remedies support gut health, though persistent severe symptoms require medical attention.
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European Association for the Study of Obesity published in Nature Medicine.
Load More
